Majito30

Epigenetic subtypes of Burkitt lymphoma #ASH25

Muy orgullos@s de nuestro residente @jburgos_tovar por el premio a la 👏🏻👏🏻mejor comunicación oral 👏🏻👏🏻 en el congreso #46SEMI “Descripción clínica y microbiológica de una serie de casos de Micobacterias No Tuberculosas entre 2018 y 2024” Enhorabuena 💥💥

ELEVATED VITAMIN B12 High vitamin B12? 🧪 Unlike deficiency, elevated B12 usually isn’t about diet or supplements. It’s often a marker of disease. ... but no consensus on whether/how to investigate! See: thebloodproject.com/elevated-vitam…

1 Acute myeloid leukemia (AML), blast morphology often provides important clues to the underlying genetics

Guía rápida: dosis de ANTICOAGULANTES ORALES DIRECTOS

Hoy es el Día Internacional de la Leucemia Linfática Crónica (LLC) #wclld25. En la actualidad, la supervivencia de la LLC es del 85% a 5 años y las terapias dirigidas han sido clave. Nuestro siguiente objetivo será mejorar la calidad de vida de pacientes y familiares 🙌🏻 @sehh_es

Excited to share our paper on Frailty Dynamics & QoL in MM patients undergoing auto-HCT a @GETH_info study is now out in @BrJHaem Thank you @QueraltSalas for your support, advices and ideas! FRAILTY MATTERS! #MultipleMyeloma #HCT #Frailty #QOL onlinelibrary.wiley.com/doi/10.1111/bj…

Respecto a la leucemia mieloide aguda con reordenamiento de MECOM, señala la respuesta falsa: A El gen partner más frecuente es GATA2 B La trombocitosis es infrecuente. C El pronóstico es muy adverso. D La displasia megacariocítica es muy prominente.

🔬 AML Classification: WHO 5th vs ICC 🩸🧵 1️⃣ WHO 5th Edition: ✅ AML with defining genetic abnormalities (no blast threshold): •🧬 Fusion: RUNX1::RUNX1T1, CBFB::MYH11, DEK::NUP214, BCR::ABL1, etc. •🧬 Rearrangements: KMT2A, MECOM, NUP98 •🧬 Molecular: NPM1, CEBPA ⚠️ If none: ➡️ AML defined by differentiation (blasts ≥20%): •AML M0, M1, M2, M4, M5, M6, M7, etc. 🩺 Separate group: •Post-cytotoxic therapy •Germline predisposition 📄 Ref: •WHO Classification of Haematolymphoid Tumours 5th Ed ⸻ 2️⃣ ICC Classification: ✅ AML with recurrent genetic abnormalities (blasts ≥10%): •RUNX1::RUNX1T1, CBFB::MYH11, DEK::NUP214, NPM1, BCR::ABL1, in-frame bZIP CEBPA ➡️ If no: ✅ AML with TP53 mutation (VAF >10%) ➡️ If no: ✅ AML with myelodysplasia-related gene mutation ➡️ If no: ✅ AML with myelodysplasia-related cytogenetic abnormality ➡️ If no: ✅ AML – NOS ⚠️ Appended qualifiers: •💉 Therapy-related •📈 Prior MDS •📈 Prior MDS/MPN •🧬 Germline predisposition ⚠️ Blast %: •10–19%: MDS/AML •≥20%: AML 📄 Ref: •ICC 2022 Haematological Malignancies Classification ⸻ 🩺 Key takeaways: ✅ ICC lowers blast threshold to 10% if recurrent genetic abnormality present. ✅ WHO retains 20% threshold unless defining genetics. ✅ Emphasis on genetics > morphology. ✅ Clear approach to therapy-related and germline AML. ⸻ 🔗 Save for #Hematology #Boards 🔗 Share with your #Pathology team 🔗 Use during #AML discussions and teaching

Te invitamos a las Jornadas Regionales de Linfoma Cutáneo en Barcelona y Madrid @geltamo 🗓️ 22 y 29 de septiembre 2025 📝Formato presencial ℹ️ geltamo.com/noticias/233-j… @DrBastosOreiroM @EvaEvagbarca Plazas limitadas!

🆕Nuevo documento "Manejo del Síndrome Antifosfolipídico (SAF)" de los GT de Enfermedades Autoinmunes Sistémicas (@gtgeassemi) y Enfermedad Tromboembólica (@GT_Trombo) de @Sociedad_SEMI🩺 👉Disponible en la web de SEMI y en la webapp "Algoritmos y protocolos de SEMI". 🔹Web SEMI (Publicaciones): fesemi.org/publicaciones/… 🔹Webapp (GT GEAS y Enf. Tromboembólica): protocolos.fesemi.org/#/ #MedicinaInterna @JavierPagan1988 @mmartinasenjo @DrGlezGarcia @gabi_puchepalao @LuisSaezComet @gerardespinosa5

Verdades de Aries 🔮

Que bonito! ❤️

📢¡No te puedes perder el I Curso #SETH JOVEN: #Hemostasia para tod@s 4.0! 📚Formación dirigida a R4 y adjuntos/as de reciente incorporación👩‍⚕️👨‍⚕️ 📅29 de abril |📍Sede #SETH, Madrid 🔗Inscripción gratuita: seth.es/i-curso-seth-j… #FormaciónSETH #hemostasia #trombosis #hematólogos #HematoEnRed @HematoCAUSA

🎙️ Avui, a les 11 h, la Dra. Elisenda Solé, adjunta al servei de Pediatria de l’Hospital Universitari #MútuaTerrassa, intervindrà al magazín “Faves comptades” de @cugatmedia. 🗣️ Parlarà de la iniciativa “Llegir ens fa créixer!”. cugat.cat/directe/index.…

Waldenström Macroglobulinemia: 2025 Update on Diagnosis, Risk Stratification, and Management |American Journal of Hematology | Blood Research Journal | Wiley Online Library onlinelibrary.wiley.com/doi/full/10.10…

¡Ya tenemos programa de H-ONCOBARNA! Curso Multidisciplinar de Patología Hematológica y Oncológica Crítica, 7-9 mayo 2025 en @vallhebron (Barcelona). Formato teórico-práctico, presencial y online. +info e inscripciones⬇️ aula.vallhebron.com/?go=info_curso… ¡Os esperamos en H-ONCOBARNA!

📢 Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) Comprehensive Review 🔬🩸 📄 Guideline-Based Approach 🎯 WHO 2022 / NCCN / BSH / ELN 🔗 Reference: WHO 5th Ed (2022), NCCN, BSH, ELN 🆘 MDS/MPN is a group of overlapping hematologic disorders with features of both myelodysplasia & myeloproliferation 🚨. Key Subtypes: 🔹 Chronic Myelomonocytic Leukemia (CMML) 🟤 🔹 Atypical Chronic Myeloid Leukemia (aCML) ⚪ 🔹 MDS/MPN with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T) 🟣 🔹 MDS/MPN Unclassifiable (MDS/MPN-U) 🔘 ⸻ 🟥 Clinical Manifestations 🏥 🔹 CMML 🟤 ✅ Monocytosis (>1 × 10⁹/L, Monocytes ≥10% WBC) ✅ Splenomegaly 🫛, Constitutional symptoms (weight loss, fever) 🌡️ ✅ Cytopenias (Anemia, thrombocytopenia) & Dysplastic BM features 🔬 ✅ Increased risk of AML progression (15-30%) 🚨 🔹 aCML ⚪ ✅ Marked Leukocytosis (>13 × 10⁹/L), Dysplastic Neutrophils 🩸 ✅ NO BCR-ABL fusion gene 🚫 ✅ Splenomegaly 🫛 ✅ High risk of AML transformation 🚨 🔹 MDS/MPN-RS-T 🟣 ✅ Ring sideroblasts ≥15% in BM 🔬 ✅ Thrombocytosis (PLT >450 × 10⁹/L) 📊 ✅ SF3B1 mutation (~90%) 🧬 ✅ Lower risk of transformation to AML 🚨 🔹 MDS/MPN-U 🔘 ✅ Mixed features of MDS & MPN but doesn’t fit other categories ✅ Highly variable prognosis & therapy 🤷‍♂️ ⸻ 🟦 Diagnostic Criteria (WHO 2022) 🔍 ✅ Overlap of dysplastic (MDS) & proliferative (MPN) features ✅ Absence of BCR-ABL1 fusion gene (excludes CML) 🚫 ✅ Absence of rearrangements in PDGFRA, PDGFRB, FGFR1, PCM1-JAK2 🚫 ✅ No previous MPN, MDS, or AML history ✅ Cytopenias (anemia, neutropenia, thrombocytopenia) ✅ Dysplastic bone marrow 🔬 🧪 Key Biomarkers: 🔹 CMML → TET2, ASXL1, SRSF2 🧬 🔹 aCML → SETBP1, ASXL1, NRAS 🧬 🔹 MDS/MPN-RS-T → SF3B1 🧬 📌 Cytogenetics: ✅ Normal or complex karyotype ✅ Del(7q), Del(5q), Trisomy 8 seen in CMML ⸻ 🟡 Differential Diagnosis ❓ 🔹 CML 🚨 🔸 BCR-ABL1+ (CML) vs. BCR-ABL1- (aCML) 🔹 MDS 🩸 🔸 More cytopenias, fewer proliferative features 🔹 MPNs (PV, ET, PMF) 🔸 No significant dysplasia 📌 Key Tests to Differentiate: — BCR-ABL1 (CML vs. aCML) 🧬 — JAK2, CALR, MPL (ET, PMF, PV vs. MDS/MPN) — SF3B1 (MDS/MPN-RS-T) ⸻ 🟢 Risk Stratification (CMML Prognostic Models - CPSS, CPSS-Mol) 🎯 ✅ Low Risk: 🎯 — WBC <13 × 10⁹/L — No ASXL1 mutation — Good cytogenetics ✅ High Risk: 🚨 — WBC >13 × 10⁹/L — ASXL1 mutation 🧬 — Complex karyotype ⸻ 🟠 Management 💊🩸 🔹 Supportive Therapy (All Patients) ✅ Transfusions for anemia (RBC) 💉 ✅ Erythropoiesis-Stimulating Agents (ESA) if low EPO 💊 ✅ Hydroxyurea for proliferative disease 💊 🔹 Disease-Modifying Therapy 🎯 ✅ Hypomethylating Agents (HMA) (Azacitidine, Decitabine) 🔬 ✅ Lenalidomide in MDS/MPN-RS-T (SF3B1-mutated cases) 💊 ✅ Ruxolitinib for JAK2+ proliferative CMML 🎯 🔹 Curative Option 🚨 ✅ Allogeneic Stem Cell Transplant (SCT) for high-risk cases 🏥 📌 Special Considerations: — CMML with high WBC → Hydroxyurea to control count — MDS/MPN-RS-T → Avoid cytoreduction unless symptomatic — Transplant in young/high-risk patients ⸻ 🔴 Complications & Monitoring 🔍 ⚠️ Thrombosis & Bleeding (MDS/MPN-RS-T) 🚨 ⚠️ Progression to AML (Highest in aCML & CMML) 🧬 ⚠️ Splenomegaly & Constitutional Symptoms 🫛 ⚠️ Cytopenias & Infections 🦠 📆 Follow-Up: — CBC & BM monitoring every 3-6 months 📊 — Mutation tracking (ASXL1, SF3B1, TET2) 🧬 — Assess splenomegaly & thrombosis risk ⸻ 📌 Key Takeaways ✅ MDS/MPN overlaps dysplastic & proliferative features 🔬 ✅ CMML = Monocytosis + Cytopenia + AML risk 🟤 ✅ aCML = Neutrophilia + Dysplasia, BCR-ABL- ⚪ ✅ MDS/MPN-RS-T = Ring sideroblasts + Thrombocytosis (SF3B1+) 🟣 ✅ Risk-based management (HMA, Hydroxyurea, SCT for high-risk) 🎯 🔬 MDS/MPN syndromes require careful risk stratification & personalized treatment! #Hematology #MDSMPN #CMML #aCML #Myeloproliferative #Leukemia #BloodCancer

Com cada dissabte podeu recuperar els continguts destacats de la setmana. Avui #8M parlem dels 15 anys del SIAD #ElPrat. També coneixerem la campanya "Llegir ens fa créixer!" @Mutua_Terrassa i la proposta literària de la psicoterapeuta Verónica Portillo. open.spotify.com/episode/3JH3sA…

🚨 ABRIL 2025 🚨 Reunión Presencial!🚨 @ICO_oncologia @HematICO_Hosp @HematoCanRuti @Hemato_Vhebron @hematosantpau @hematoclinicbcn #CARTalunya